F S&P 500
5,534.00 -3.00 (-0.05%) F Dow Jones
39,429.00 -97.00 (-0.25%) F Nasdaq
19,991.50 +19.25 (+0.10%) E-mini Russell 2000 Index Futur
2,036.00 -8.90 (-0.44%) Petróleo
81.34 +0.51 (+0.63%) Oro
2,320.20 -10.60 (-0.45%)
Longboard Pharmaceuticals, Inc. (LBPH)
Fuera de horario:
Longboard Pharmaceuticals, Inc.
4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
858-789-9283
https://www.longboardpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 50
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kevin R. Lind | President, CEO, Secretary & Director | 1.07M | N/D | 1976 |
| Ms. Brandi L. Roberts CPA, M.B.A. | Executive VP & CFO | 662.65k | N/D | 1974 |
| Dr. Randall E. Kaye M.D. | Executive VP & Chief Medical Officer | 717.95k | N/D | 1962 |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Operations | N/D | N/D | N/D |
| Megan E. Knight | VP & Head of Investor Relations | N/D | N/D | N/D |
| Mr. Steven W. Spector J.D. | Executive VP, Head of Business Development & General Counsel | N/D | N/D | 1965 |
| Dr. Anne M. Danks Ph.D. | VP & Head of Nonclinical Research & Development | N/D | N/D | N/D |
| Mr. Gus Cardenas | VP & Head of Quality Assurance | N/D | N/D | N/D |
| Dr. Marco Peters Ph.D. | VP & Head of Translational Science | N/D | N/D | N/D |
| Dr. Dewey McLin Ph.D. | VP & Head of Medical Affairs | N/D | N/D | N/D |
Descripción
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Longboard Pharmaceuticals, Inc. a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 7; Junta: 10; Derechos del accionista: 8; Compensación: 8.
